Wednesday 19th January Digital therapeutics company PneumoWave (formerly known as Altair Medical) announced today the use of their monitoring platform...
Tuesday 2nd November Digital therapeutics company PneumoWave (formerly known as Altair Medical) announced today the commencement of a second clinical...
Wednesday 20th October Altair Medical, (“Altair”) aims to revolutionize care for respiratory symptoms and diseases with its advanced, remote respiratory monitoring...
Monday 24th February Altair Medical, a medical technology company developing a groundbreaking solution to the global opioid crisis, today announce that...
PneumoWave raises £7.5 million Series A to accelerate clinical validation and regulatory submission of respiratory change diagnosis and monitoring platform
PneumoWave Featured in the Scotsman
Dr Gary Cooney appointed as Mental Health Lead
Dundee University start RESCU trial of PneumoWave’s wearable biosensor device aiming to cut opioid overdose deaths
PneumoWave & King’s College London Collaborate in Clinical Trial
PneumoWave and NHS Greater Glasgow & Clyde Announce Clinical Trial Aiming to Reduce Deaths from Respiratory Depression
Rebrand of Altair Medical to PneumoWave
Altair Medical secures $3.1m in Pre-Series A financing
Storm ID, Altair Medical & NHS GGC develop a respiratory monitoring service for COVID-19 patients in new clinical trial
Altair Medical accelerates development schedule by adopting FDA cleared cloud data management platform
Altair medical achieves FDA breakthrough status